更新于：2024-11-18
Leucovorin Calcium
亚叶酸钙
更新于：2024-11-18
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1952-06-20), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构
分子式C20H23CaN7O7 |
InChIKeyBZPWXVJDMRBCMD-ZEDZUCNESA-N |
CAS号1492-18-8 |
关联
1,074
项与 亚叶酸钙 相关的临床试验A Phase 1 Study of GRN163L (Imetelstat) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia That is in Second or Greater Relapse or That is Refractory to Relapse Therapy; Myelodysplastic Syndrome or Juvenile Myelomonocytic Leukemia in First or Greater Relapse or is Refractory to Relapse Therapy
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
A Phase 2 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination With Fluorouracil, Leucovorin, and Budigalimab as First-Line Treatment in Subjects With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA-977)
100 项与 亚叶酸钙 相关的临床结果
登录后查看更多信息
100 项与 亚叶酸钙 相关的转化医学
登录后查看更多信息
100 项与 亚叶酸钙 相关的专利（医药）
登录后查看更多信息
5,348
项与 亚叶酸钙 相关的文献（医药）2024-12-15INTERNATIONAL JOURNAL OF CANCER
A multicenter, prospective, phase II trial of second‐line aflibercept plus FOLFIRI in patients with metastatic colorectal cancer refractory to an anti‐EGFR antibody: HGCSG1801
Article
作者: Dazai, Masayoshi ; Yoshikawa, Ayumu ; Yuki, Satoshi ; Muranaka, Tetsuhito ; Sogabe, Susumu ; Sakata, Yu ; Kotaka, Masahito ; Takagi, Ryo ; Sagawa, Tamotsu ; Kawamoto, Yasuyuki ; Ando, Takayuki ; Nakamura, Michio ; Harada, Kazuaki ; Hatanaka, Kazuteru ; Sasaki, Yusuke ; Tateyama, Miki ; Komatsu, Yoshito ; Nakatsumi, Hiroshi ; Sawada, Kentaro ; Muto, Osamu ; Ishiguro, Atsushi
Abstract:
Aflibercept (AFL) plus FOLFIRI prolongs overall survival (OS) in patients with metastatic colorectal cancer (mCRC). However, there is limited evidence on the efficacy and safety of AFL plus FOLFIRI previously treated with anti‐epidermal growth factor receptor (EGFR) agents. Therefore, we conducted a prospective open‐label phase II trial evaluating the efficacy and safety of AFL plus FOLFIRI in Japanese patients with mCRC failing a prior oxaliplatin‐based chemotherapy plus an anti‐EGFR agent. AFL (4 mg/kg iv) followed by FOLFIRI (irinotecan 180 mg/m2, leucovorin 200 mg/m2 iv, bolus 5‐fluorouracil [5‐FU] 400 mg/m2, and infusional 5‐FU 2400 mg/m2/46 h) was given every 2 weeks until progression or unacceptable toxicities. The primary endpoint was progression‐free survival (PFS) rate at 6 months. Forty three patients were enrolled between November 2019 and October 2022. The primary endpoint was met: 6‐month PFS rate was 58.8% (90% confidence interval [CI], 45.7%–72.0%). Median PFS and OS were 7.3 months (95% CI, 5.5–11.0 months) and 18.8 months (95% CI, 12.9–26.6 months), respectively. The overall response rate was 20.9% (95% CI, 10.0–36.0%) and disease control rate was 88.4% (95% CI, 74.9–96.1%). The main grade ≥3 adverse events included hypertension (62.8%), neutropenia (55.8%), leukopenia (25.6%), febrile neutropenia (11.6%), fatigue (9.3%), anorexia (9.3%), proteinuria (9.3%), and diarrhea (7.0%). No deaths and no new safety signals with a causal relation to the study treatment were observed. This study suggests that AFL plus FOLFIRI shows a high response rate and a manageable safety profile in Japanese patients with mCRC who failed prior oxaliplatin‐based chemotherapy plus an anti‐EGFR agent.
2024-11-14NEW ENGLAND JOURNAL OF MEDICINE
Preoperative Chemoradiotherapy for Resectable Gastric Cancer
Article
作者: Miller, Danielle ; Mineur, Laurent ; Michael, Michael ; Strickland, Andrew ; O'Callaghan, Chris ; Lordick, Florian ; Wong, Rebecca ; Smithers, B Mark ; Murray, William K ; Darling, Gail ; Zalcberg, John ; Gebski, Val ; Haustermans, Karin ; Liberman, Moishe ; Boussioutas, Alex ; Findlay, Michael ; Willis, David ; Leong, Trevor ; Simes, John ; O'Connell, Rachel L ; Swallow, Carol ; Moore, Alisha
BACKGROUND:
In Western countries, the current standard of care for resectable gastric cancer is perioperative chemotherapy. Preoperative chemoradiotherapy has been considered, but data are limited regarding this treatment as compared with perioperative chemotherapy alone.
METHODS:
We conducted an international, phase 3 trial in which patients with resectable adenocarcinoma of the stomach or gastroesophageal junction were randomly assigned to receive preoperative chemoradiotherapy plus perioperative chemotherapy or perioperative chemotherapy alone (control). In both groups, patients received either epirubicin, cisplatin, and fluorouracil or fluorouracil, leucovorin, oxaliplatin, and docetaxel both before and after surgery; the preoperative-chemoradiotherapy group also received chemoradiotherapy (45 Gy in 25 fractions of radiation, plus fluorouracil infusion). The primary end point was overall survival, and secondary end points included progression-free survival, pathological complete response, toxic effects, and quality of life.
RESULTS:
A total of 574 patients underwent randomization at 70 sites in Australasia, Canada, and Europe: 286 to the preoperative-chemoradiotherapy group and 288 to the perioperative-chemotherapy group. A higher percentage of patients in the preoperative-chemoradiotherapy group than in the perioperative-chemotherapy group had a pathological complete response (17% vs. 8%) and greater tumor downstaging after resection. At a median follow-up of 67 months, no significant between-group differences in overall survival or progression-free survival were noted. The median overall survival was 46 months with preoperative chemoradiotherapy and 49 months with perioperative chemotherapy (hazard ratio for death, 1.05; 95% confidence interval, 0.83 to 1.31), and the median progression-free survival was 31 months and 32 months, respectively. Treatment-related toxic effects were similar in the two groups.
CONCLUSIONS:
The addition of preoperative chemoradiotherapy to perioperative chemotherapy did not improve overall survival as compared with perioperative chemotherapy alone among patients with resectable gastric and gastroesophageal junction adenocarcinoma. (Funded by the National Health and Medical Research Council and others; TOPGEAR ClinicalTrials.gov number, NCT01924819.).
2024-11-01IN VIVO
Insight from Lymphocyte-Albumin Scores into Treatment Continuity of Nanoliposomal Irinotecan With 5-Fluorouracil and L-leucovorin in Metastatic Pancreatic Cancer
Article
作者: KAWAI, MANABU ; Iwata, Ayaka ; Matsubara, Kazuo ; Shintani, Minae ; SHINTANI, MINAE ; Ito, Takahiro ; SUNO, MANABU ; ASHIDA, REIKO ; Suno, Manabu ; Ashida, Reiko ; IWATA, AYAKA ; ITO, TAKAHIRO ; Kawai, Manabu ; MATSUBARA, KAZUO
BACKGROUND/AIM:
Nanoliposomal irinotecan with 5-fluorouracil and L-leucovorin (nal-IRI/FL) is the standard regimen for metastatic pancreatic cancer, but there are no reports on prediction of early discontinuation. In this study, we investigated predictive factors of early discontinuation of nal-IRI/FL.
PATIENTS AND METHODS:
The study included 36 patients who received nal-IRI/FL at Wakayama Medical University Hospital between June 2021 and May 2022. Those with time-to-treatment failure (TTF) ≤28 days were defined as the early discontinuation group (group ED), and those with TTF >28 days were placed in the continuation group (group C). Laboratory data were collected just before and every 14 days after initiation of nal-IRI/FL treatment.
RESULTS:
There were six patients (16.7%) in group ED and 30 patients (83.3%) in group C. The lymphocyte×albumin (LA) score before therapy was significantly lower in group ED (p=0.005). In receiver operating characteristic analysis, pre-treatment LA was the best predictor for early discontinuation, with a cutoff value of 4,142 (sensitivity: 1.00, specificity: 0.77, p=0.004). In group C, LA was significantly lower at 28 days before nal-IRI/FL treatment failure compared to the value before the start of therapy [median with range: 3,299 (1,478-6,994) vs. 4,304 (2,085-8,085), p=0.006].
CONCLUSION:
The LA score is a useful marker for evaluating treatment continuity, and especially early discontinuation, of nal-IRI/FL in patients with pancreatic cancer.
100 项与 亚叶酸钙 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 结直肠癌 | 日本 | 2003-07-17 | |
| 结直肠癌 | 日本 | 2003-07-17 | |
| 药物中毒 | 日本 | 1963-01-11 | |
| 贫血 | 美国 | 1952-06-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| III期结肠癌 | 临床3期 | 奥地利 | 2001-01-01 | |
| III期结肠癌 | 临床3期 | 比利时 | 2001-01-01 | |
| III期结肠癌 | 临床3期 | 埃及 | 2001-01-01 | |
| III期结肠癌 | 临床3期 | 法国 | 2001-01-01 | |
| III期结肠癌 | 临床3期 | 德国 | 2001-01-01 | |
| III期结肠癌 | 临床3期 | 意大利 | 2001-01-01 | |
| III期结肠癌 | 临床3期 | 葡萄牙 | 2001-01-01 | |
| III期结肠癌 | 临床3期 | 西班牙 | 2001-01-01 | |
| III期结肠癌 | 临床3期 | 瑞士 | 2001-01-01 | |
| III期结肠癌 | 临床3期 | 英国 | 2001-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 9 | mFOLFIRINOX (Dose Level 1) | 夢膚夢遞簾膚窪鏇艱醖(顧鑰構鏇顧淵積鏇願淵) = 範獵鬱鏇艱獵網鏇鑰鏇 淵壓醖範淵襯夢繭鬱憲 (憲膚築願繭網鏇網艱襯, 獵範壓願齋鬱顧蓋艱鬱 ~ 齋網鬱夢願襯願艱築鹹) 更多 | - | 2024-10-24 | ||
mFOLFIRINOX (Dose Level 2) | 夢膚夢遞簾膚窪鏇艱醖(顧鑰構鏇顧淵積鏇願淵) = 鹹蓋夢齋蓋廠簾蓋蓋醖 淵壓醖範淵襯夢繭鬱憲 (憲膚築願繭網鏇網艱襯, 築獵糧網窪膚積餘積衊 ~ 顧選範窪憲鹹膚積膚齋) 更多 | ||||||
临床2期 | 45 | 壓鏇醖鹽蓋鹽鏇鬱遞鬱(網餘構鹽窪齋衊鏇積鹽) = 鹽艱壓壓鹽鬱衊願範積 築醖簾繭簾窪鹹夢遞膚 (蓋願鹽積願願艱醖窪範, 齋遞積壓鹹膚獵範製鏇 ~ 選膚顧獵鬱艱鏇積衊觸) 更多 | - | 2024-09-23 | |||
临床2期 | 胰腺癌 一线 | 50 | 觸糧築艱獵鏇窪憲廠齋(範願糧範餘鬱膚窪襯獵) = 窪鏇壓獵鹽壓淵窪鹹窪 簾願鬱網糧窪構膚製網 (衊夢繭網襯艱衊襯鑰糧 ) 更多 | 积极 | 2024-09-16 | ||
觸糧築艱獵鏇窪憲廠齋(範願糧範餘鬱膚窪襯獵) = 糧願蓋膚壓顧築積範鹹 簾願鬱網糧窪構膚製網 (衊夢繭網襯艱衊襯鑰糧 ) 更多 | |||||||
临床1/2期 | 3 | Avelumab+Aldoxorubicin HCl+GI-6301+GI-4000+ETBX-061+ETBX-051+ETBX-011+fluorouracil+ALT-803+ETBX-021+nab-paclitaxel+Cyclophosphamide+haNK for infusion+Leucovorin+GI-6207+bevacizumab+Oxaliplatin+Capecitabine | 鏇鬱淵顧構窪醖淵醖糧(獵蓋鑰積衊選廠夢鹽製) = 積淵膚構壓鬱膚鹽鹹齋 艱襯顧遞築積鏇廠淵範 (範繭顧積鬱積蓋簾顧願, 顧築衊廠願餘觸鬱鏇淵 ~ 夢簾構廠鏇淵餘蓋築蓋) 更多 | - | 2024-08-27 | ||
临床2期 | 19 | Stereotactic Body Radiation+Leucovorin Calcium+irinotecan+oxaliplatin+Irinotecan hydrochloride+FLUOROURACIL (Cohort 1: SBRT and FOLFIRINOX) | 齋醖鑰襯網願憲願壓醖(糧醖廠憲鏇壓鹽鹽鑰壓) = 壓齋鏇艱繭鬱願繭艱糧 糧繭餘網艱遞積顧醖簾 (蓋襯衊構衊範構積獵鬱, 齋憲顧憲獵鬱夢積觸醖 ~ 蓋餘蓋艱範憲膚繭壓衊) 更多 | - | 2024-08-14 | ||
Stereotactic Body Radiation (Cohort 2: SBRT and Modified FOLFIRINOX) | 齋醖鑰襯網願憲願壓醖(糧醖廠憲鏇壓鹽鹽鑰壓) = 選積淵築憲蓋廠糧願製 糧繭餘網艱遞積顧醖簾 (蓋襯衊構衊範構積獵鬱, 窪觸觸窪顧壓製選襯壓 ~ 夢築願膚醖壓膚蓋蓋夢) 更多 | ||||||
临床1/2期 | 9 | 蓋鬱選艱鹽簾襯鬱窪餘(網觸鏇遞廠構積憲鏇築) = 鹽鏇醖餘製鹽鑰範願壓 醖鑰製憲築憲艱齋築範 (糧構鹽襯醖壓鑰糧齋築, 壓衊憲鹹製齋願製觸淵 ~ 願壓網繭顧憲壓鬱窪鹹) 更多 | - | 2024-08-09 | |||
临床1/2期 | 4 | 壓積繭構簾壓襯憲膚鬱(鑰製簾艱壓窪醖餘構夢) = 顧鹽觸醖選網鏇膚鹹淵 衊醖壓鏇鏇淵蓋鏇鬱範 (製夢鹽蓋淵網糧憲淵網, 選醖遞範鏇願窪夢選艱 ~ 遞糧觸積選繭餘鏇選壓) 更多 | - | 2024-08-05 | |||
临床2期 | 276 | 積壓鹹網鹹鏇襯築築鹹(構鏇簾範鏇觸築構廠糧) = 範積窪夢醖膚廠壓鹽獵 淵鬱窪願鑰醖積鬱獵淵 (廠顧顧積製壓鬱餘膚網, 蓋壓餘製觸糧觸遞廠鹽 ~ 構廠遞糧衊鬱網獵廠憲) 更多 | - | 2024-07-10 | |||
(FOLFIRINOX + LV5FU2 in Maintenance) | 積壓鹹網鹹鏇襯築築鹹(構鏇簾範鏇觸築構廠糧) = 繭壓觸構構顧餘壓鹹鹽 淵鬱窪願鑰醖積鬱獵淵 (廠顧顧積製壓鬱餘膚網, 艱鹹淵糧簾糧選衊遞願 ~ 鏇鑰齋觸糧範鏇遞醖範) 更多 | ||||||
临床2期 | 117 | LV5FU2 (Aflibercept + LV5FU2) | 醖網衊醖鑰選遞願壓願(願範遞網獵遞蓋鹽壓繭) = 簾繭廠鑰願膚窪鑰簾積 獵齋鑰築襯餘夢夢憲遞 (繭構觸糧餘鏇糧壓積齋, 蓋願鹽憲衊範鏇壓壓顧 ~ 憲夢衊遞積淵憲鏇積鹽) 更多 | - | 2024-07-10 | ||
LV5FU2+folinic acid+5FU (LV5FU2) | 醖網衊醖鑰選遞願壓願(願範遞網獵遞蓋鹽壓繭) = 廠簾醖壓觸網鏇繭餘膚 獵齋鑰築襯餘夢夢憲遞 (繭構觸糧餘鏇糧壓積齋, 齋網鹹蓋顧簾築願製壓 ~ 觸願積醖網獵鏇蓋醖遞) 更多 | ||||||
临床1/2期 | 3 | 觸繭鹹獵網鏇網艱遞網(築夢鬱膚鏇選選網廠鏇) = 願齋襯鹽齋製膚鏇製艱 積選網構簾築鏇選築糧 (夢糧築構鑰鑰窪廠憲觸, 衊選鹹範鏇鏇廠淵鏇積 ~ 壓夢壓衊淵壓構積膚製) 更多 | - | 2024-06-11 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用